Home Finance Teva moves anti-IL-15 antibody to Phase 2b for vitiligo treatment
Finance

Teva moves anti-IL-15 antibody to Phase 2b for vitiligo treatment

Share
Teva moves anti-IL-15 antibody to Phase 2b for vitiligo treatment
Share


Teva moves anti-IL-15 antibody to Phase 2b for vitiligo treatment

Source link

Share

Leave a comment

Leave a Reply

Your email address will not be published. Required fields are marked *